A summarised guide to Genomics

The average size of artificial intelligence (AI) deals was significantly higher than deals across the wider UK equity market in 2024, underlining the continued focus on the sector, reveals the British Business Bank’s annual Small Business Equity Tracker, published today.

The Data (Use and Access) Act became law last week – but what does it mean for the life science sector? Fredericka Argent, Paul Maynard, and Tom Griffiths from Covington and Burling’s technology regulatory team explain all in this blog.

Brainomix and 3DR Labs announced a new strategic partnership to support acute stroke care in the US through the clinically validated and FDA-cleared Brainomix 360 Stroke.

Revolutionary network of national scanners accelerates diagnosis and drug development to deliver patient benefit

Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven drug discovery (AIDD) platform by combining the power of generative AI with brain-inspired methodologies.

From a multi-billion-pound boost to R&D and life sciences manufacturing, to scaling innovative businesses through the British Business Bank, the Review signals significant investment.